UniProtKB/Swiss-Prot P01583: Variant p.Arg85Gln

Interleukin-1 alpha
Gene: IL1A
Feedback?

Variant information Variant position:

85 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Arginine (R) to Glutamine (Q) at position 85 (R85Q, p.Arg85Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from large size and basic (R) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs3783531 [ dbSNP | Ensembl ]

Sequence information Variant position:

85 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

271 The length of the canonical sequence.
Location on the sequence:

LTFKESMVVVATNGKVLKKR R LSLSQSITDDDLEAIANDSE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LTFKESMVVVATN---GKVLKKRRLSLSQSITDDDLEAIANDSE

                              LTFKENVVVVAAN---GKILKKRRLSLSQFITDDDLEGIAN

Rhesus macaque                LTFKQSMVVVSTN---GKVLKKRRLSLSQSITDNNLEAIAN

Mouse                         FTFKESRVTVSATSSNGKILKKRRLSFSETFTEDDLQSITH

Rat                           FTFKESRVVVSATSNKGKILKKRRLSFNQPFTEDDLEAIAH

Pig                           LNFKDSVVMAAAN---GKILKKRRLSLNQFITDDDLEAIAN

Bovine                        LSFKENVVMVAAS---GKILKKRRLSLNQFITDDDLEAIAN

Rabbit                        LTFQENVVAVTAS---GKILKKRRLSLNQPITDVDLETNVS

Goat                          LSFKENVVMVTAN---GKILKKRRLSLNQFITDDDLEAIAN

Sheep                         LSFKENVVMVTAN---GKILKKRRLSLNQFITDDDLEAIAN

Cat                           LTLKKSVVMVAAN---GKILKKRRLSLNQFLTADDLEAIAN

Horse                         LNFKESVVLVAAN---GKTLKKRRLSLNQFITNDDLEAIAN

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Propeptide	1 – 112
Region	82 – 86	Nuclear localization signal (NLS)
Modified residue	82 – 82	N6-acetyllysine
Modified residue	87 – 87	Phosphoserine
Lipidation	82 – 82	N6-myristoyl lysine
Lipidation	83 – 83	N6-myristoyl lysine
Glycosylation	102 – 102	N-linked (GlcNAc...) asparagine
Mutagenesis	82 – 82	K -> Q. About 50% loss of cytokine secretion after DNA damage.

Literature citations
Submission
SeattleSNPs variation discovery resource;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS GLN-85; SER-114 AND ASN-138;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.